Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by 1H-magnetic resonance spectroscopy in a rat model

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 2, 2011, Pages 356-363

  Marsman, Hendrik A ^a   Heger, Michal ^a   Kloek, Jaap J ^a   Nienhuis, Syert L ^a   Van Werven, Jochem R ^b   Nederveen, Aart J ^b   Ten Kate, Fiebo J W ^b   Stoker, Jaap ^b   Van Gulik, Thomas M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Fatty liver; Liver transplantation; Treatment

Indexed keywords

CHOLINE; INTERLEUKIN 6; METHIONINE; OMEGA 3 FATTY ACID; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FATTY LIVER; GAS CHROMATOGRAPHY; HISTOPATHOLOGY; LIPID DIET; LIPOGENESIS; LIVER FUNCTION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT;

EID: 78851471191     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06326.x     Document Type: Article

References (33)

1. Middleton PF, Duffield M, Lynch SV etal. Living donor liver transplantation-adult donor outcomes: a systematic review. Liver Transpl. 2006; 12: 24-30.
2. Marsman WA, Wiesner RH, Rodriguez L etal. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246-51.
3. Vetelainen R, van Vliet A, Gouma DJ etal. Steatosis as a risk factor in liver surgery. Ann. Surg. 2007; 245: 20-30.
4. McCormack L, Petrowsky H, Jochum W etal. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann. Surg. 2007; 245: 923-30.
5. Vetelainen R, van Vliet AK, van Gulik TM. Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. Ann. Surg. 2007; 245: 44-50.
6. Selzner M, Clavien PA. Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. Hepatology 2000; 31: 35-42.
7. Selzner M, Rudiger HA, Sindram D etal. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000; 32: 1280-8.
8. Barr ML, Belghiti J, Villamil FG etal. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation 2006; 81: 1373-85.
9. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin. Liver Dis. 2001; 21: 43-55.
10. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J. Hepatol. 2005; 42: 928-40.
11. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-31.
12. Lin HZ, Yang SQ, Chuckaree C etal. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 2000; 6: 998-1003.
13. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 282: G193-9.
14. Ijaz S, Yang W, Winslet MC etal. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003; 10: 447-56.
15. Nakamuta M, Morizono S, Soejima Y etal. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation 2005; 80: 608-12.
16. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004; 39: 608-16.
17. Alwayn IP, Gura K, Nose V etal. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr. Res. 2005; 57: 445-52.
18. El-Badry AM, Moritz W, Contaldo C etal. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology 2007; 45: 855-63.
19. Sekiya M, Yahagi N, Matsuzaka T etal. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 1529-39.
20. Vetelainen R, van Vliet AK, van Gulik TM. Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. J. Gastroenterol. Hepatol. 2007; 22: 1526-33.
21. Marsman HA, Werven van JR, Nederveen AJ, Kate ten FJW, Stoker J, Gulik van TM. Nonvasive quantitative assessment of hepatic steatosis in the rat liver using 3.0 Tesla 1H-Magnetic Resonance Spectroscopy. Br. J. Surg. 2008; 95: S6. Abstract.
22. Naressi A, Couturier C, Devos JM etal. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 12: 141-52.
23. Longo R, Pollesello P, Ricci C etal. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J. Magn. Reson. Imaging 1995; 5: 281-5.
24. Srivastava NK, Pradhan S, Mittal B etal. An improved, single step standardized method of lipid extraction from human skeletal muscle tissue. Anal. Lett. 2006; 39: 297-315.
25. Kleiner DE, Brunt EM, van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
26. Kloek JJ, Marsman HA, van Vliet AK etal. Biliary drainage attenuates postischemic reperfusion injury in the cholestatic rat liver. Surgery 2008; 144: 22-31.
27. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002; 56: 365-79.
28. Araya J, Rodrigo R, Videla LA etal. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. 2004; 106: 635-43.
29. Puri P, Baillie RA, Wiest MM etal. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-90.
30. Goheen SC, Larkin EC, Rao GA. Severe fatty liver in rats fed a fat-free ethanol diet, and its prevention by small amounts of dietary arachidonate. Lipids 1983; 18: 285-90.
31. Alwayn IP, Andersson C, Zauscher B etal. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 2005; 79: 606-8.
32. Fishbein TM, Fiel MI, Emre S etal. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997; 64: 248-51.
33. Gonzalez-Periz A, Horrillo R, Ferre N etal. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 2009; 23: 1946-57.